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cost-effectiveness frontier generated by the average costs and benefits of each 
technology may mask inter-dependencies between technologies. Parameter val-
ues that render one technology efficient may render another inefficient, and vice 
versa. There can also be uncertainty about which interventions appear on the 
frontier, and the adoption of approaches to select competing interventions solely 
on the basis of being on the efficiency frontier may be unreasonable.
PRM82
Validating an indolent non-Hodgkin’s lyMPHoMa (nHl) Cost-
effeCtiVeness analysis Model Using two softwaRe tools: key 
iMPleMentation ConsideRations and ResUlts
Wehler E.A.1, Bilir S.P.2, Bertwistle D.3, Leyva V.4, Munakata J.2
1IMS Health, Alexandria, VA, USA, 2IMS Health, San Francisco, CA, USA, 3IMS Health, London, 
UK, 4IMS Health, Mexico City, Mexico
Objectives: The ISPOR-SMDM Modeling Good Research Practices Task Force 
highlights the importance of model transparency and validation, including 
cross validation, as a means to establishing trust and confidence in economic 
models. (1) To investigate how a technical model validation can be conducted by 
reconstructing a previously-developed Microsoft Excel cost-effectiveness model 
using TreeAge; and, (2) to validate the model by comparing the results of two 
implementations. MethOds: An Excel-based cohort model on indolent NHL was 
reconstructed in in TreeAge using the same model structure, clinical inputs, and 
costing assumptions. Lifetime costs, life-years, quality-adjusted life-years, and 
incremental cost-effectiveness ratios (ICERs) were projected and compared for 
bendamustine-rituximab (Ben-R) versus fludarabine-rituximab (Fdb-R) in relapsed 
indolent NHL patients in Colombia. All costs were in 2013 Colombian pesos. The 
base-case results and sensitivity analyses were compared between the two soft-
ware tools and key implementation considerations were identified. Results: 
Key differences in the two software tools were identified and implementation 
differences will be described, including handling of survival inputs and applica-
tion of one-time and per-cycle costs. The TreeAge model produced more favorable 
results compared to the Excel model. The total costs for Ben-R and Fdb-R were 
$223,400,660 and $208,115,352 in the TreeAge model, respectively, while in the 
Excel model they were $291,192,912 and $260,463,392. The ICERs were $11,582,974/
LY and $13,815,417/QALY in the TreeAge model and $23,286,360/LY and $27,956,124/
QALY in the Excel model. However, once the differences between the two models 
were accounted for in implementation, the reconstructed TreeAge model produced 
approximately the same results compared to the original Excel model (23,381,795/
LY vs. $23,286,360/LY). cOnclusiOns: There are inherent differences in model 
implementation in Excel vs. TreeAge that should be considered when performing 
double implementation and when interpreting the model results. Model valida-
tion using two software tools is a practical way to ensure proper and intended 
implementation.
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Objectives: Different modeling approaches have been used to estimate the cost-
effectiveness of antipsychotics used to reduce psychotic symptoms of schizo-
phrenia. This study systematically reviewed schizophrenia modelling studies, to 
examine the relationship between the modeling approach used in schizophrenia 
studies and their reported outcomes. MethOds: A systematic literature review of 
MEDLINE, EconLit, Embase, and the Cochrane Library and an Internet search iden-
tified published results of schizophrenia modeling studies from 2000 to 2011. Two 
independent reviewers performed searches according to a prespecified protocol 
limited to English-language articles from any country. Results: Eighty-three pub-
lications reported 80 individual modelling studies that met the inclusion criteria. 
Fifty-seven studies reported results of 71 pairs of antipsychotic drug comparisons 
(drug A vs. drug B) as incremental cost-effectiveness ratios (ICERs), such as cost per 
quality-adjusted life-year (QALY), which allowed a comparison of results. The major-
ity of the economic evaluations used a Markov (23 studies) or decision-tree model 
23 studies); 9 studies used a discrete-event simulation (DES) model, and 2 studies used 
a microsimulation model. Among the 11 comparisons with contradictory results, we 
focused on the following drug comparisons of atypical antipsychotics with the most 
studies: risperidone long-acting injection versus oral olanzapine, oral risperidone ver-
sus oral olanzapine, oral risperidone or oral olanzapine versus ziprasidone, and oral 
olanzapine versus oral aripiprazole. Overall, model structure, time horizon, and patient 
population did not affect study results. Differences among studies with contradictory 
results generally reflected definition of response and relapse rates in the health states, 
validity of clinical data sources for transition probabilities, and assignment of utilities 
to estimate QALYs. cOnclusiOns: The cost-effectiveness results of the majority of 
models were in agreement regardless of the model structure. In models with contra-
dictory results, most differences could be explained by definition of response, relapse, 
discontinuation, or adverse-event rates and/or by the selection of sources.
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Objectives: A novel prognostic test is being developed to predict cancer-related 
mortality in early non-small cell lung cancer (NSCLC) to inform the use of adju-
PRM79
assessing tHe signifiCanCe of HBa1C dURaBility in Cost 
effeCtiVeness analysis of 2nd line oRal tHeRaPies in tHe 
ManageMent of tyPe 2 diaBetes
Foos V.1, McEwan P.2, Palmer J.L.3, Lamotte M.4, Grant D.5
1IMS Health, Basel, Switzerland, 2Swansea University, Cardiff, UK, 3IMS Health, Allschwil, Basel-
Landschaft, Switzerland, 4IMS Health HEOR, Vilvoorde, Belgium, 5IMS Health, London, UK
Objectives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
therapy escalation or intensification is often required to maintain acceptable 
levels of glycaemic control. The objective of this study was to assess how dif-
ferential dual therapy failure rates influence the cost effectiveness (CE) results in 
T2DM. MethOds: This study used the IMS Core Diabetes Model (CDM), a validated 
and established diabetes model, to evaluate the CE of metformin+ sulphonylurea 
(M+S) compared to metformin + DPP-4 (M+D). Efficacy data for dual therapy was 
sourced from a published systematic review; HbA1c and BMI change of -0.8% and 
0.199kg/m2 (M+D) and -0.79% and 0.707kg/m2 (M+S) respectively were applied. 
Rates of severe hypoglycaemia were 0.1612 and 1.538 per 100 patient years and 
4.596 and 68.769 per 100 patient years for non-severe events in M+D and M+S 
respectively. Insulin rescue therapy was initiated at an HbA1c threshold of 7.5%. 
Base case analysis assumed M+D and M+S had the same HbA1c durability; lifetime 
CE was assessed assuming improvement in durability favouring M+D applied 
in 10% increments with costs (US$) and benefits discounted at 3.5%. Results: 
In the base case analysis, annual HbA1c increase was 0.26% with mean time 
to therapy escalation of 5 years; and a predicted cost per quality adjusted life 
year (QALY) of $211,948. Mean annual increments in HbA1c for M+D of 0.182%, 
0.13% and 0.1% were necessary to achieve costs effectiveness at willingness to 
pay (WTP) thresholds of $100,000, $70,000 and $50,000 respectively. Published 
HbA1c durability for M+D of 0.052% per year was associated with a cost per QALY 
of $33,427. cOnclusiOns: This analysis demonstrates that the annual rate of 
increase in HbA1c exerts considerable influence over predicted CE and is therefore 
an important variable to study when assessing the CE of new interventions for 
the management of T2DM.
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The efficacy of plant sterols in reducing plasma LDL-cholesterol has been dem-
onstrated. In 2009, the European Food Safety Agency stated that for an intake of 
1.5-2.4g/day plant sterols, an average reduction of LDL blood cholesterol from 7% 
to 10.5% can be expected and such a reduction is of biological significance in terms 
of reduced risk of coronary heart disease. In France, the consumption of plant-
sterols enriched products (PSEP) was part of the official dietary recommendations 
for hypercholesterolemic subjects when the study was designed. Objectives: 
The objective was to assess the cost-effectiveness of a daily consumption of PSEP, 
in the context of a healthy diet, on statin’s initiation delay from the consumer 
perspective, in the eligibleat risk French population. MethOds: A 1 year cycle 
Markov model was built to estimate the benefit (i.e. delay/avoid statins’ initiation) 
in a French population aged between 45 and 65 years and at risk of drug treatment 
according to the French Drug Agency recommendations. Information on the evolu-
tion of cholesterol level and the different cardiovascular disease risk factors was 
retrieved in the literature. Costs of statin treatment duration avoidance (i.e. price 
of PSEP fully paid by the consumers) was estimated according to age and gen-
der. Results: The eligiblepopulation included in the model was respectively 49% 
and 66% among the French male and female population between [45;65 y]. Based 
on the selected assumptions, and assuming that healthy diet is already integrated 
in lifestyle habits, daily cost per statin free life year due to substitution of usual 
dairy product by a PSEP was estimated at 0.71€ /day and 1.01€ /day respectively for 
male and female. cOnclusiOns: This exploratory work allowed getting a first 
estimation of the cost-effectiveness of the daily consumption of PSEP, from the 
consumer perspective in accordance with official dietary recommendations for 
cholesterol management.
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Objectives: The cost-effectiveness efficiency frontier is typically generated by 
plotting the costs and benefits for a variety of technologies, often summarised 
as the mean across a large number of simulations. However, the mean across 
simulations may mask correlations between technologies within simulations. We 
sought to investigate these issues using a HTA comparing 19 different interven-
tions. MethOds: We compared 19 different breast cancer surveillance strategies 
for women aged less than 50 years with a BRCA1 mutation. We calculated the 
cost-effectiveness efficiency frontier for 5,000 simulations and also based on the 
mean costs and benefits for each strategy. We also investigated the probability 
of a strategy appearing on the frontier and correlations between whether or not 
different strategies appeared on the frontier. Results: The efficiency frontier 
based on means included 6 strategies. This was the cost-effectiveness efficiency 
frontier in only 22 (0.44%) of 5,000 simulations. Forty four other frontiers were more 
likely to be generated by simulations. Two strategies not on the frontier of means 
had a substantial probability of being on the frontier. Some strategies were nega-
tively correlated such that the appearance of one strategy on the frontier never 
or seldom co-occurred with another. These negative correlations also occurred 
between strategies that appeared on the frontier of means. cOnclusiOns: The 
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Objectives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
validation the model’s outcomes needs to be compared to outcomes of cohorts that 
were not used for the modeling exercise. The objective of this study was to demon-
strate the methods and results of the external validation. MethOds: As a first step, 
we identified the applicable clinical trials and cohort studies which had not been 
used to build the model and simulated the patient cohorts for each study according 
to the published demographic, epidemiologic characteristics and treatment pat-
terns. The incidence rates of the predicted and observed outcomes were calculated 
for comparison and the results were evaluated using statistical methods and expert 
opinion. Results: 92 validation analyses were performed. The differences between 
the estimated and measured values of the incidences were within the range of 
44% and -100%. The slope of the fitted linear regression line was 0.5326 while the 
R2 value was 0.6956. The macular oedema submodel presented the best fit and the 
estimated values from the foot ulcer submodel had the lowest accuracy compared 
to values observed in other studies. cOnclusiOns: In overall the model performed 
well, however it frequently underestimated the incidence of the outcomes observed 
in the studies. This is most likely due to the limited information about the patient 
characteristics from the studies under evaluation. In most cases the information 
published about the population characteristics, treatment patterns and effective-
ness were not sufficiently detailed to precisely match the model’s input parameters. 
Without sufficient information average values were used as input parameters, and 
this way the model presumably simulated healthier patient cohorts than the ones 
participated in the studies.
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Objectives: Within acute coronary syndromes (ACS), the risk of experiencing fatal 
and non-fatal cardiac events is highest immediately after diagnosis and decreases 
over time. Visual inspection of survival curves from pivotal ACS trials suggest three 
potential risk periods. The highest risk (unstable disease) period typically lasts up to 
10 days from diagnosis. Patients then become more stable but are still at a high risk 
of events until approximately 30 days from diagnosis. Beyond 30 days patients are 
considered stable and at a lower risk of events. Different agents may be best suitable 
for different periods and may affect different events. The objective of this research is 
to estimate a model which enables the effects on fatal and non-fatal events follow-
ing an ACS episode to be disentangled and that distinguishes between periods of dis-
ease without accurately knowing how long these periods are. MethOds: A Markov 
model is estimated which distinguishes between three time periods and between 
fatal and non-fatal events. A likelihood function is derived as well as a Bayesian pro-
cedure to estimate the model parameters. The approach is tested using simulated 
data. Subsequently, event free survival data and overall survival data comparing 
ticagrelor with clopidogrel are taken from the Kaplan-Meier curves presented in the 
publication of the PLATO trial and model parameters are estimated based on these 
data. Results: Using simulated data the model mimics the data generating process 
perfectly and the approach seems quite powerful in distinguishing periods and dif-
ferences with patient numbers of 500 and above. cOnclusiOns: When applied to 
the PLATO study we conclude from the model that ticagrelor lowers the probability 
to experience an event in the unstable and stable high risk disease periods.
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Objectives: Emergence of long-term side effects of treating Parkinson’s disease 
(PD) patients with levodopa, particularly dyskinesia (levodopa induced dyskinesia - 
LID), limit the ability to optimally treat symptoms and consequences of PD. PD-LID 
interferes with performance of activities of daily living, ambulation and balance 
and increases health care costs. There are no approved treatments and no stud-
ies examining cost-effectiveness of an intervention for PD-LID. Objective of the 
present study is to develop a de-novo economic model to identify the value drivers 
for a drug to be cost-effective for treatment of PD-LID. MethOds: The model com-
bines a short-term (6 months) decision tree, to determine initial response to the 
drug, with a long-term Markov approach to model transition of patients across LID 
severity over lifetime. The model classifies LID severity using modified Abnormal 
Involuntary Movement scale (mAIMS) with disease states defined as mild (0-12), 
moderate (13-18) and severe (19-24). Disease state specific costs included costs 
of drug treatments, consultations/visits, paramedical services, laboratory tests, 
radiological examinations, hospitalizations, community/social services and 
unpaid services. State specific utilities were calculated and assigned based on 
literature. Results: The model suggests that initial response to the treatment, 
ability to improve and halt worsening dyskinesia health states are the greatest 
value drivers of the treatment for PD-LID. More than 90% of costs were driven 
by medical costs. A treatment for PD-LID that results in 6-month response rate 
of at least 50%, 25% increase in the probability of dyskinesia improving and 25% 
reduction in the probability of dyskinesia worsening results in a 0.28 QALY gain 
per patient. cOnclusiOns: This economic analysis suggests that a health care 
intervention that could improve the clinical parameters of dyskinesia can have 
significant beneficial impact on costs and utilities. Further studies are required 
vant chemotherapy (ACT). The collection and assessment of data inputs for a U.S. 
economic model evaluating this prognostic will be reported. MethOds: Medline 
and Tuft’s CEA Registry were searched for model parameters using the following 
terms and MeSH headings: NSCLC, adjuvant chemotherapy, recurrence, utilization, 
economics, cost, quality of life, utility, cost-effectiveness/-utility/-benefit. Inclusion 
criteria were randomized controlled trials (RCTs), meta-analyses, heath technology 
assessments, North American and European studies, quality of life analyses, and 
early lung cancer. Results were limited to full text and English articles. We also 
assessed relevant references listed in these articles. Results: The search yielded 
one meta-analysis and 7 RCTs assessing ACT in resected NSCLC. These studies 
report survival (HR 0.75-0.95 favoring ACT), ACT toxicity (30-85% experiencing grade 
3-4 toxicity), and stage distribution (Stage IA-7.6%, IB-29.9%, II-35.3%, III-27.2%). They 
also include disease free survival (HR 0.66-0.93 favoring ACT), but not stratified by 
NSCLC stage. Monthly cost of NSCLC was found in two studies (initial $5,255-11,496, 
continuing $2,602-3,733, terminal $9399-16,470). Two studies reported the U.S. cost of 
ACT toxicity ($4,629-9,516 per grade 3-4 event). Three studies reported utility values 
specific to early NSCLC including one with values related to ACT and toxicity with 
values varying from 0.60 to 0.75. Data reporting current U.S. ACT utilization was not 
identified. cOnclusiOns: Early NSCLC literature contains the majority of data 
inputs necessary for this model. Limitations exist, specifically regarding recurrence 
by stage, current ACT utilization and cost of health care resources. These limitations 
can be overcome using expert opinion, assumptions for guideline adherence and/
or conducting observational studies to inform the model.
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Objectives: Stroke–one of the leading causes of death and disability–represents 
substantial clinical and economic burden. Understanding treatment patterns and 
causative relations may help e.g. to identify outcomes predictors and cost driv-
ers. MethOds: We used Polish Hospital Stroke Registry data on patient baseline 
characteristics (demographics, risk factors, prestroke disability, stroke severity), 
hospital management, treatment outcomes and drugs (pre-admission, during hos-
pitalisation, and prescribed at discharge). We used inferred causation approach that 
deducts causal (not associative) interpretations from patterns of (conditional) inde-
pendence. In this primary analysis we used 5000 observations from 2007/2008 year, 
binary variables and assumed no hidden variables. We used Tetrad 4.3.10-6 with PC 
algorithm. Variables were grouped into five tiers, a priori forbidding some directions 
of causal influence. Large number of variables led us to a restrictive significance 
level (α = 0.0001). Results: New insight can be gained from existence, lack of, and 
the direction of causal relations. Our results: confirmed (without imposing prior 
knowledge) the use of cardiovascular drugs in relation with underlying risk factors 
and natural sequence of drug management (drugs used prior to, in acute stroke 
and at discharge); surprisingly suggested no causal relation between some clinical 
characteristics and drug use (e.g. history of stroke/diabetes and oral anticoagulants) 
or acute stroke treatment (e.g. aspirin, thrombolysis, stroke unit based treatment) 
and mortality/post-stroke disability; determined the causal direction between 
some risk factors (e.g hypertension and diabetes, gender and AF) or patient history 
and prestroke disability (history of stroke or age over 75 and impaired disability); 
could not unambiguously discover the causal-relation between stroke unit based 
treatment and unproven efficacy drugs use. cOnclusiOns: Apart from statistical 
or econometric approach, causal-type reasoning can be used both to confirm the 
intuition, and to detect new patterns in data. Further research should include the 
possibility of hidden variables and try to quantify the causal relations.
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Objectives: To a) to perform a systematic literature review to identify existing 
models for cost-effectiveness analysis of disease modifying anti rheumatic drugs 
in Rheumatoid Arthritis, and b) to develop and test a method for the selection of 
a model that is transferable to the Dutch health care setting by simple adapta-
tion. MethOds: We searched Medline and Embase to identify relevant studies in 
the English language between 1-1-2002 and 31-8-2012. For studies that met the 
inclusion criteria, we applied a 3-step approach in model selection. First, models 
that did not meet all minimal methodological requirements based on the OMERACT 
criteria were excluded. Second, the models were assessed based on their fit when 
transferred to the Dutch health care setting. Transferability factors as published by 
Welte et al., except for those that were deemed transferable by simple adaptation, 
were used for this ranking procedure. Finally, the remaining models underwent 
a general quality check using the Philips checklist. Models showing good fit and 
high quality were considered to be transferable to the Dutch health care setting 
using simple adaptation. Results: The systematic literature search resulted in 498 
papers, which included 33 unique health economic models. Only six models passed 
the OMERACT methodological requirements. Two of these models had imperfect 
transferability fit according to Welte. The remaining four models were, according 
to Philips, of good quality and were expected to be transferable by a simple adapta-
tion. cOnclusiOns: This study introduces a stepwise approach to the identifica-
tion and selection of health economic models that are transferable by a simple 
adaptation. This approach can be applied in various therapeutic areas, provided that 
the minimal methodological requirements are defined accordingly. Availability of 
health economic models coupled with structured model selection could improve 
the efficiency, quality and comparability of health economic evaluations.
